By evaluating the copy number aberration (CNA) in bone marrow cells and/or circulating cell free DNA (cfDNA) via shallow whole genome sequencing (sWGS), in conjunction with conventional cytogenetics, LeukoPrint® makes leukemia diagnosis, molecular subtyping, prognostic stratification and treatment responds monitoring more precise and comprehensive.
Without culturing cells in vitro
High sensitivity and low failure rate
Automatic readout system
An example of CNA profiling of LeukoPrint® reveals abnormal karyotype at molecular level
◉ Indicated subjects：Patients with suspected or confirmed leukemia (MDS/AML/ALL/CLL/MM)
◉ Sample requirement：1-2ml bone marrow or 10ml blood